Optiver Holding
SPRY icon

Optiver Holding’s ARS Pharmaceuticals SPRY Stock Holding History

Optiver Holding’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.6K Buy
324
+64
+25% +$613 ﹤0.01% 1742
2025
Q4 		$3.03K Sell
260
-96
-27% -$934 ﹤0.01% 1746
2025
Q3 		$3.58K Buy
+356
New +$5.11K ﹤0.01% 2055

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Optiver Holding's SPRY Position: Q1 2026 in Review

Optiver Holding increased its ARS Pharmaceuticals (SPRY) stake by 25% in Q1 2026, buying an estimated $613 and bringing the position to 324 shares worth $2.6K. The position accounts for ﹤0.01% of the portfolio, ranked #1742.

Optiver Holding first reported a position in SPRY in Q3 2025 and has held it in 3 quarters since. The position peaked at $3.58K in Q3 2025. 202 funds tracked by Wall St. Rank hold SPRY as of Q1 2026.

  • Optiver Holding held 324 shares of ARS Pharmaceuticals worth $2.6K as of Q1 2026.
  • Optiver Holding bought 64 ARS Pharmaceuticals shares in Q1 2026, an estimated $613.
  • ARS Pharmaceuticals made up ﹤0.01% of Optiver Holding's portfolio in Q1 2026, its #1742 holding.
  • Optiver Holding first reported a position in ARS Pharmaceuticals in Q3 2025 and has held it in 3 quarters since.
  • Optiver Holding's ARS Pharmaceuticals position peaked at $3.58K in Q3 2025.
  • 202 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q1 2026.

Based on Optiver Holding's 13F filing for Q1 2026, filed 15 May 2026.